Background: Patients with medically managed type B aortic dissection (TBAD) have a high incidence of aorta-related complications over time. Whereas early thoracic endovascular aortic repair (TEVAR) to seal the entry tear can promote aortic remodeling and prevent late aneurysm formation, there are sparse data as to which patients will benefit from such therapy. The goal of this study was to identify clinical and anatomic factors that are associated with the need for subsequent aortic intervention in patients who present with uncomplicated TBAD. These factors could guide the selection of patients who will benefit from TEVAR in the subacute phase.
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Questions
1,2 The standard of care for patients who present with an acute uncomplicated type B aortic dissection (TBAD) has been medical management because of favorable 1-year survival compared with open replacement of the descending thoracic aorta in uncomplicated patients. [3] [4] [5] Indeed, surgical intervention has traditionally been reserved for patients who present with complicating conditions, such as aortic rupture and malperfusion syndrome. However, medical management alone is associated with a 40% incidence of aneurysmal dilation of the outer wall of the false lumen in the first 5 years, and many of these patients will require open repair of extensive thoracoabdominal aneurysms. [6] [7] [8] [9] Coverage of the proximal entry tear with thoracic endovascular aortic repair (TEVAR) has replaced open repair in most patients with acute complicated TBAD. Several prospective trials that focused on the use of TEVAR in patients with complicated TBAD have shown that the 30-day mortality is 5% to 16%. [10] [11] [12] This is significantly lower than the 30% mortality reported after intervention for complicated TBAD in the original International Registry of Acute Aortic Dissection (IRAD) report. 13 Indeed, in most aortic centers, including those that participate in IRAD, TEVAR has become first-line therapy for anatomically suitable patients with complicated TBAD. 11, 12 In addition, long-term follow-up of patients who have undergone TEVAR for acute TBAD shows that aortic remodeling occurs along the stented segment of the aorta, thus preventing aneurysmal degeneration, which would clearly be the impetus for considering TEVAR in patients with uncomplicated TBAD.
11
The Investigation of Stent Grafts in Aortic Dissection (INSTEAD) trial randomized patients with subacute, uncomplicated TBAD into TEVAR and best medical therapy cohorts. Although there was no difference in 1-year all-cause mortality between the groups and the 2-year survival was actually lower in the TEVAR cohort, survival at 5 years favored the patients who had been treated with TEVAR.
14 These data were confirmed by a recent IRAD study in which the 5-year survival was significantly higher in TBAD patients treated with TEVAR compared with those who were medically treated. 15 Our recent study of the natural history of medically managed patients with acute TBAD showed that the intervention-free survival was only 41% after 6 years. 16 Thus, it is clear that medical therapy alone does not prevent aortic degeneration in many patients with TBAD. However, TEVAR in the acute setting can be complicated by paraplegia and stroke, such that its use in low-risk patients is unwarranted. There is currently a paucity of data that can be used to determine a patient's risk for development of aortic degeneration after acute TBAD. The goal of this study was to identify clinical and anatomic factors that are associated with the need for late aortic intervention in patients who present with uncomplicated TBAD. These data should inform clinicians as to which patients will benefit from TEVAR in the subacute phase.
METHODS
Creation of patient cohort. Partners Healthcare maintains a centralized clinical data registry of all inpatient and outpatient encounters within the system. This database, the Research Patient Data Registry, was searched for the International Classification of Diseases, Ninth Revision code for patients with aortic dissection who presented to the Massachusetts General Hospital between January 2000 and December 2013. Patients were included if they had axial imaging that confirmed the entry tear was distal to the left subclavian artery and presented within 14 days of the development of symptoms. Patients with type A dissections (Stanford A or DeBakey type I/II) were excluded from the study, as were those with complicated TBADs (eg, malperfusion syndrome or rupture). Patients were also excluded if they did not have serial imaging studies available to assess aortic maximal diameter change. The Massachusetts General Hospital Institutional Review Board approved the protocol for this study, and individual patient consent was waived.
Clinical definitions. A patient was considered to have a history of hypertension if the initial history and physical documented that the patient was previously receiving antihypertensive medications or had a diagnosis of hypertension. Coronary disease was defined as medical therapy for coronary vascular disease or prior coronary revascularization. Similarly, chronic obstructive pulmonary disease and connective tissue disorders were documented if they were present as diagnoses on the initial inpatient documentation. Diabetes mellitus was defined by presence of medical treatment (either insulin or oral antiglycemics). End-stage renal disease was defined by the need for renal replacement therapy. Antihypertensive medications were also recorded if they were being taken on initial presentation.
Outcomes. Procedural and outcome variables were collected from all inpatient and outpatient encounters through December 2013. The size of the entry tear was measured on axial imaging using coronal and sagittal reconstructions. Aortic diameters were measured using the largest outer to outer contour diameter. Complete thrombosisdwith no contrast material evident in the false lumendwas necessary for the designation of false lumen thrombosis. The presence of a free-floating dissection flap (ie, the entire circumference of the aorta was dissected) was also assessed on axial imaging.
The primary outcome measure was need for aortic intervention to treat a complication of the TBAD. This included the development of malperfusion syndrome, aneurysmal degeneration of the thoracic aorta, and death. Aneurysmal degeneration was defined as increase in the total aortic diameter of >5.5 cm or growth of $0.5 cm in a 6-month period. This was measured over time and expressed in life-table format. The decision to use an open or endovascular approach for intervention was surgeon dependent and based on the indication for intervention, timing from initial presentation, and anatomic factors. The majority of late procedures were open thoracoabdominal repairs performed for aneurysm degeneration, whereas early intervention was more likely to be secondary to malperfusion and was treated through an endovascular approach. All deaths within 30 days of an aortic intervention were collected through a review of the electronic medical record and Social Security Death Index. To better understand the natural history of medically managed TBAD, patients who underwent intervention were stratified into early (within 180 days of initial presentation) and late (181 days or later) cohorts.
Statistical analysis. Freedom from intervention and survival were calculated using Kaplan-Meier life tables. Univariate predictors of intervention were also determined using life-table analysis. A Cox proportional hazards multivariate model was created to determine predictors of late aortic intervention. Data were analyzed with SAS 9.4 software (SAS Institute, Cary, NC). A P value of <.05 was considered statistically significant.
RESULTS
During the nearly 14-year study period, 920 patients with symptoms of acute aortic syndrome presented to the Massachusetts General Hospital. Of the 920 patients, 534 were excluded with type A aortic dissections and 92 presented with a complicated TBAD requiring immediate operative intervention. Of the remaining 294 patients who were initially treated with medical therapy alone, 254 had multiple axial imaging studies and were included in the study cohort. The cohort as a whole had a mean age of 66.3 6 15.8 years, and 65% were men. Most patients were hypertensive at initial presentation, and the majority of patients were taking multiple antihypertensive medications (Table I) .
During a median follow-up period of 6.8 years, 97 patients (38.2%) ultimately underwent an aortic intervention. The 30-day operative mortality after these interventions was 6.2%. An open intervention was performed in 64 patients (66%), and an endovascular approach was used in 33 patients. The most common indication for an aortic intervention was aneurysmal degeneration, seen in 83.5% of interventions (Table II) .
Thirty patients (11.8%) with uncomplicated TBAD underwent an aortic intervention within the first 180 days (range, 32-178 days); 67 (26.3%) patients underwent a late aortic intervention (after 181 days). Two groups were formed for univariate analysisdintervention vs no intervention. On univariate analysis, no difference was noted between the groups in regard to demographic data (age, gender, race, presence of comorbidities). There were statistically significant differences in aortic anatomy between the two groups. The patients in the intervention group were more likely to have larger dissection entry tears >10 mm (33.5% vs 12.8%; P ¼ .02). The intervention group also had a larger total aortic diameter at initial presentation (40.6 mm vs 30.8 mm; P ¼ .01). Indeed, 58% of patients in the intervention group had an aortic diameter >40 mm compared with only 21% in the intervention-free cohort (P ¼ .01). The presence of a freely floating dissection flap trended toward statistical significance in the intervention group (4.1% vs 1.9%; P ¼ . 19 Life-table (Kaplan-Meier) analysis of the two groups (intervention vs medical management) revealed that survival was significantly better in the operative intervention group (78.4% 6 4.8%) than in the medically treated cohort (53.8% 6 4.0%; P ¼ .02) as shown in Fig 2. 
DISCUSSION
The traditional treatment strategy for uncomplicated acute TBAD has been medical therapy with aggressive blood pressure control and serial imaging. This approach was supported by multiple studies that showed favorable 1-year survival (72%-90%) with medical therapy compared with early open repair. 3, 17, 18 However, the consequence of medical management of acute TBAD is the future development of thoracoabdominal aneurysms secondary to degeneration of the outer wall of the false lumen. 19 Indeed, a recent study from our institution looked at 200 patients with medically managed TBAD and found that 51% of patients experienced aortic growth at 5 years and 28% required operative intervention (most were open thoracoabdominal aneurysm repairs) for aneurysmal degeneration. 20 TEVAR has been shown to reduce this risk by promoting remodeling of the aorta through true lumen expansion and false lumen thrombosis in the stented segment of the aorta.
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In addition, a recent report from the IRAD registry compared 1129 consecutive patients with TBAD and found that patients who had their entry tear sealed with TEVAR had a survival advantage at 5 years over those who were treated with medical therapy alone (85% TEVAR vs 71% medical; P ¼ .018). 15 These promising results with TEVAR in patients with complicated TBAD coupled with the recent Food and Drug Administration blanket approval of TEVAR for the treatment of TBAD increase the likelihood that TEVAR will become the standard of care for many patients with uncomplicated TBAD. The issue, of course, will be selection of patients. Our previous work showed that most comorbidities, such as hypertension and coronary artery disease, do not predict aneurysm growth, so it will most likely be anatomic factors that prompt early intervention. 20 The goal of this study was to help establish anatomic parameters that can guide clinical decision-making as to the worth of early TEVAR in uncomplicated TBAD. A previously published report from our institution showed that a total aortic diameter >35 mm correlated with the development of aneurysmal degeneration over time. 16 However, in this study, when multiple anatomic measurements were included in the hazard models, the smaller total aortic diameter of 35 mm was no longer significant on multivariate analysis, and the size threshold that predicted the future development of aneurysm-related events increased to 40 mm. Winnerkvist et al followed up 66 patients with uncomplicated TBAD for an average of 79 months and found an initial aortic diameter of >40 mm to be predictive of aortic events. 5 Similarly, Marui et al retrospectively reviewed 141 patients with medically managed TBAD and found fusiform dilation of the aorta, patent false lumen, and initial aortic diameter >40 mm to be predictive of late aortic events. In that study, patients who had all three aortic findings had an event-free survival of 8% at 10 years, whereas 90% of patients with none of these predictors were event free at 10 years. 21 This 40-mm threshold appears to be consistently predictive of aneurysmal degeneration and should be used to consider early TEVAR in patients with uncomplicated TBAD. [21] [22] [23] However, aortic diameters between 35 and 40 mm remain a concern, and patients who present in this range should be monitored closely with a shorter time to the first follow-up imaging (within 3-6 months) to look for early aortic growth. In this study, patients who presented with an entry tear >10 mm were more likely to require a future intervention. The size of the entry tear has been found to be a predictor of dissection-related events and poor overall prognosis in other series as well. Evangelista et al followed up 76 medically treated TBAD patients for >6 years and found that entry tear size predicted aorta-related events and allcause mortality. 24 In that study, the size of entry tear was treated as a continuous variable such that the risk of both negative outcomes increased with every millimeter increase in the size of the entry tear. One explanation for this is that a larger entry tear allows a higher volume of blood to enter the false lumen. This raises the systolic pressure in the false lumen, leading to an increase in wall stress that promotes aneurysmal growth. 25 Covering larger entry tears with TEVAR depressurizes and obliterates the false lumen, which in turn blunts aortic growth and promotes remodeling. 11 In this study, the size of entry tear was dichotomized, and $10 mm was identified as the threshold that predicted late intervention. A free-floating or circumferential aortic dissection in which the true lumen is completely dissociated from the aortic wall is rare in TBAD. 26 In our experience, this is often associated with compression of the true lumen that leads to dynamic obstruction and the malperfusion syndrome. In this scenario, the patient would require early intervention, so it is not surprising that there were only seven patients with a free-floating true lumen included in the study. Despite the low power of this anatomic finding, there was a trend toward predicting a need for aortic intervention. Hence, the presence of a free-floating true lumen should inform the clinician that there is a high probability the patient will require an intervention. In multiple prior studies, persistent false lumen flow has been a consistently demonstrated risk factor for late aneurysm formation.
21,23,24,27-29 Akutsu et al followed up 110 patients with medically managed TBAD, of whom 48 (44%) had a patient false lumen, and patency of the false lumen was an independent risk factor for dissection-related intervention and death. 27 Tsai et al reviewed 201 TBAD patients from the IRAD registry who survived initial hospitalization. Only 9.5% of patients had a completely thrombosed false lumen and 57% had a completely patent false lumen. Interestingly, the presence of partial thrombosis of the false lumen predicted 3-year mortality compared with a completely patent lumen. 29 This may be explained by the number and location of entry tears along the dissection flap. Patients with a patent false lumen likely have multiple distal fenestrations that equalize the mean arterial pressures between the true and false lumens. However, with partial thrombosis, the distal fenestrations are thrombosed, so blood flows through the proximal entry tear, and with no pathway of outflow, the mean arterial pressure in the false lumen is increased. 29 Thus, coverage of the proximal entry tear in this scenario with TEVAR should induce total false lumen thrombosis and promote aortic remodeling. Indeed, in this study, the presence of a totally thrombosed false lumen was protective against adverse aorta-related events.
Because of the retrospective nature of this study, anatomic assessment of the aorta was limited to a static computed tomography (CT) scan obtained at the time of presentation. There is new evidence that dynamic imaging with positron emission tomography-CT scanning may help identify patients with acute TBAD and inflammation that may predict future aneurysmal degeneration. One tracer that has been used to evaluate patients with TBAD is 18 F-fluorodeoxyglucose. Several small studies have shown that the mean standardized uptake values of 18 F-fluorodeoxyglucose in TABD are higher in patients who have negative aorta-related outcomes (eg, rupture, need for surgical intervention) compared with those who do not. 30, 31 This technology is in its infancy, but it is likely that in the future, dynamic positron emission tomography-CT imaging will be part of the initial workup of patients with acute TBAD. Either way, the importance of consistent serial imaging in these patients must be stressed as those who fail to follow up are at risk of aneurysm degeneration and rupture.
CONCLUSIONS
It is clear from the literature that TEVAR has proved to be an effective way to manage patients with acute complicated TBAD with improved aortic remodeling and longterm survival compared with medical therapy alone. Thus, it is intuitive that the indications for TEVAR would be expanded to include patients with uncomplicated TBAD who are at high risk for aorta-related complications in the future. This study identified three anatomic findings that are associated with an increased need for aortic intervention after TBAD, including a maximal initial aortic diameter of >40 mm, large ($10 mm) entry tear, and freefloating true lumen. Patients who present with these anatomic findings should be considered for elective TEVAR 14 to 90 days after presentation with acute TBAD. 
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